Table 4.

The adverse drug reactions (ADRs) at 26-week follow-up period (SS = 95).

ADRs	Number of patients (%)
Nervous system disorders
Akathisia	32 (33.7%)
Extrapyramidal diseases	23 (24.2%)
Investigations
Weight gain	16 (16.8%)
Elevated blood prolactin level	15 (15.8%)
Psychiatric disorders
Anxiety	5 (5.3%)
Insomnia	5 (5.3%)
Cardiac disorders
Palpitation	8 (8.4%)
Sinus bradycardia	5 (5.3%)
Gastrointestinal disorders
Constipation	6 (6.3%)
Endocrine disorders
Hyperprolactinemia	11 (11.6%)
General disorders and administration site conditions
Fatigue	6 (6.3%)
Metabolic and nutritional diseases	5 (5.3%)